Helsinki, Finland – February 2025 – The Therapeutic Goods Administration (TGA) of Australia has granted market approval for MVision AI’s MR-based segmentation models included in Contour+. The approved models—Male Pelvis MR T2, Male Pelvis MR Dixon, and Brain MR—enable more effective and consistent radiation therapy treatment planning.
MVision AI’s MR models integrate AI-driven segmentation with MRI scans, simplifying the contouring process and ensuring a more streamlined approach to patient care. With TGA market approval, MVision AI’s MR segmentation tools assist clinicians in delivering reliable and more personalised patient care.
This regulatory milestone reflects MVision AI’s ongoing commitment to advancing AI technology in radiation oncology,
said Mahmudul Hasan, Founder and Executive Director of MVision AI.
By integrating AI-driven segmentation with MRI, we are helping clinicians improve their planning processes, providing a more streamlined and effective way to deliver care.
MVision AI continues its partnership with alphaXRT, its distributor for Australia and New Zealand, to support the adoption of its AI-driven segmentation tools across clinics and hospitals in the region. As annual cancer rates in Australia are projected to exceed 200,000 by 2034, the role of MRI and AI-driven solutions like MVision AI’s will continue to expand.
The MR models are part of MVision AI’s Guideline-Based Segmentation (GBS™) solution, which combines contouring knowledge and AI-driven automation for standardised, efficient treatment planning. The GBS™ solution includes Contour+, Guide, and Verify, tools that work together to strengthen MVision AI’s mission of delivering intelligent automation to radiation oncology.
For more information about MVision AI’s MR models and comprehensive AI segmentation solutions, contact us.
About MVision AI
MVision AI is a leading provider of AI-powered solutions for radiation therapy treatment planning. Our mission is to empower Radiation Oncology professionals with cutting-edge technology to streamline workflows, enhance treatment quality, and facilitate more patient-focused care. With a commitment to innovation and excellence, MVision AI continues to advance cancer care through the power of AI.